Title:
【発明の名称】化合物
Document Type and Number:
Japanese Patent JP2002521375
Kind Code:
A
Abstract:
Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is aryl or a mono or bicyclic heteroaryl, each of which can be optionally subsituted with one or more subsituents; Z is -X(CRR)aCO, -NH, -CO or the group X-(CH2)bCONH (CH2)cNH where X is oxygen, sulphur, amino, alkylamino or a direct bond, R and R are independently hydrogen or C1-4 alkyl, a is an integer from 1 to 4, b is 1 or 2 and c is from 2 to 5, and; W is -NHCH(R)CO- or OC(R)CHNH where R is -CH2CH(CH3)2-CH2CH2S(CH3) or CH2CH2S(O2)(CH3); q is 0 or 1 and when q is 0 Z is linked to the group W by the formation of an amide bond between Z and Y, and when q is 1 Z is linked to the group W by the formation of an amide bond between Z and W and W is linked to the group Y by the formation of an amide bond between W and Y; Y is a fragment derived from the C-terminus of a compound which inhibits the interaction between the integrin alpha IIb beta 3 and its ligand fibrinogen; R<1> is hydrogen, C1-5alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.
Inventors:
David Robert Britain
Craig John Stone
Gareth Morse Davis
Michael Stewart Large
Craig John Stone
Gareth Morse Davis
Michael Stewart Large
Application Number:
JP2000561179A
Publication Date:
July 16, 2002
Filing Date:
July 20, 1999
Export Citation:
Assignee:
AstraZeneca Actie Borak
International Classes:
A61K31/423; A61K31/428; A61K31/4439; A61P1/04; A61P3/10; A61P9/10; A61P11/06; A61P13/12; A61P17/06; A61P19/02; A61P25/00; A61P37/06; C04B41/45; C04B41/81; C07D263/58; C07D277/82; C07D405/12; C07D413/12; C07D413/14; C07D417/12; C07D417/14; (IPC1-7): C07D263/58; A61K31/423; A61K31/428; A61K31/4439; A61P1/04; A61P3/10; A61P9/10; A61P11/06; A61P13/12; A61P17/06; A61P19/02; A61P25/00; A61P37/06; C07D277/82; C07D413/12; C07D413/14; C07D417/14
Attorney, Agent or Firm:
Toshio Yano (3 outside)